收藏切换
Progress in clinical research on immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
收藏切换
Tao LIU, Ding YU, An-qi YANG, Xun-qiang WANG
Chinese Journal of New Drugs | 2021, 30(16) : 1483 - 1488
Less
收藏切换
Chinese Journal of New Drugs | 2021, 30(16): 1483-1488
Progress in clinical research on immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
Full
Tao LIU, Ding YU, An-qi YANG, Xun-qiang WANG
Affiliations
  • Department of Clinical Medicine, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing 211100, China
Published: 2021-08-30
Outline
收藏切换

Hepatocellular carcinoma (HCC) is the main pathological type of primary liver cancer, accounting for 75%~85%, and most of the patients are diagnosed late with poor prognosis. The treatment choices of advanced HCC are limited, sorafenib and other targeted drugs can only prolong the overall survival of patients to about one year, which is difficult to meet the clinical needs, so it is urgent to develop new treatment methods. Nivolumab further prolongs the overall survival of patients, and it was the first immune checkpoint inhibitor (ICI) approved for the treatment of advanced HCC, which also opened the prelude of immunotherapy for advanced HCC. Subsequent clinical studies indicated that immune checkpoint inhibitors (ICIs) combined with other therapies such as targeted therapy, local treatment, systemic chemotherapy could not only enhance the efficacy, but also had no significant increase in adverse reactions. In conclusion, ICIs have broad application prospects in the treatment of advanced HCC, and combination therapy will be the main treatment for advanced HCC.

advanced hepatocellular carcinoma  /  immune checkpoint inhibitors  /  progression of disease
刘涛, 于鼎, 杨安琪, 王训强. 免疫检查点抑制剂在晚期肝细胞癌治疗中的临床研究进展. 中国新药杂志, 2021 , 30 (16) : 1483 -1488 .
Tao LIU, Ding YU, An-qi YANG, Xun-qiang WANG. Progress in clinical research on immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma[J]. Chinese Journal of New Drugs, 2021 , 30 (16) : 1483 -1488 .
Year 2021 volume 30 Issue 16
39
10
Cite this Article
BibTeX
Article Info
  • Online Date:2026-10-28
  • Published:2021-08-30
Article Data
Affiliations
History
  • Accepted:2021-05-24
Affiliations
    Department of Clinical Medicine, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing 211100, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT